Good MorningThe S&P 500 advanced Thursday, cheering the Fed's decision to cut rates by fifty basis points. The question is if the market can hold the gains, and the answer is, at best, maybe. While the Fed's decision indicates inflation has cooled, the aggressive pace and outlook raise doubt about current economic health. With labor data softening, the US economy may be on the brink of recession now, and it is too late for the FOMC to stop it.
Risk aside, assuming the Fed has threaded the needle to its soft landing, volatility will likely remain elevated because of sector rotation. With the Fed reducing rates and easing the economic headwind, two years of the S&P 500 winding up on higher rates and the AI bubble are about to unwind in favor of small and mid-cap stocks.
Featured: Washington's Shocking Move: Your Savings Aren't Safe Anymore (Ad) 
|
Markets | |
Investors cautious about the Federal Reserve's September rate cut—confirmed at its mid-month meeting to be a full 50 basis points—and skeptical about the strength of the dollar have flocked to gold, sending the most famous safe haven commodity soaring to record highs. But there is only... Read the Full Story |
|
From Our Partners | | The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings.
Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds.
If any of these are in your portfolio, now is the time to review your positions. | | See the 5 stocks to avoid |
|
Medical | |
Edgewise Therapeutics (NASDAQ: EWTX) is up 50% in a single session and 450% from recent lows for a reason. Its novel, oral, selective treatment for obstructive hypertrophic cardiomyopathy did remarkably well in early trials. The news is important because hypertrophic cardiomyopathy or HCM for shor... Read the Full Story |
|
Markets | |
With the Federal Open Market Committee (FOMC) cutting interest rates by a larger-than-expected 50 basis points in its September meeting, businesses throughout the country will be able to take out loans more cheaply. One intended goal of a rate cut like this is to foster increased profitability thr... Read the Full Story |
|
From Our Partners | | Pilots never skip their pre-flight checklist - and neither should options traders. The Smart Trade Options Checklist covers the 7 most critical checks in about 30 seconds, helping you catch losing trades before you enter them.
Normally $29.97, it's available free for a limited time. Download it now and run it before every trade. | | Download the Smart Trade Options Checklist free before the link expires |
|
Technology | |
Since powering to several all-time highs in June and July, shares of Microsoft Corp (NASDAQ: MSFT) have been struggling to regain momentum. Equities, in general, had a solid first half of the year, but interest rate jitters and a general softening of sentiment towards tech brought about some volat... Read the Full Story |
|
Technology | |
Alphabet (NASDAQ: GOOGL), the tech giant behind Google, has seen a recovery in recent days, with shares climbing nearly 6% over the past five days. However, despite this recent bounce, the stock remains down nearly 17% from its 52-week high, weighed down by market rotation and ongoing antitrust ... Read the Full Story |
|
From Our Partners | | A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big Tech and Washington policymakers. It can be trucked to a data center, military base, or industrial site and deliver reliable power for years without grid access.
A key government milestone expected this August could bring significant visibility to this space. One small stock sits at the center of it. | | Read the full breakdown and see which stock to watch now |
|
Technology | |
Verizon's (NYSE: VZ) stock price is amid a technical reversal and will likely advance 45% or more. After years of sluggish growth and uncertainty driven by the pandemic, the 5G industry is set to boom in 2025. The forecast is for widening us driven by increased network availability and use cases f... Read the Full Story |
|
Finance | |
The FOMC gave the market what it wanted: a 50-basis point interest rate cut and an outlook for aggressive cuts to continue through the end of next year. As good as the news is, the outcome is that there is as much uncertainty about the future as there has been all year and a rising risk of heighte... Read the Full Story |
|
Retail/Wholesale | |
When there is uncertainty in the stock market, investors should pay more attention than usual to Wall Street analyst ratings and price target adjustments. These analysts rarely stick their necks out and risk their reputations – and careers when they make new calls during high-volatility even... Read the Full Story |
|
Consumer Staples | |
General Mills (NYSE: GIS) can provide a hedge if volatility continues to plague the S&P 500. The company is amid a business transformation telegraphed in its price action, which is set up for a significant reversal after more than a year of lackluster performance.
The transformation includ... Read the Full Story |
|
Medical | |
Viking Therapeutics Inc. (NASDAQ: VKTX), a clinical-stage biotechnology company with a market cap approaching $7 billion, is turning heads in 2024. Year to date, the stock has surged an impressive 238%, and its rise over the past 12 months has been even more dramatic, with shares climbing 326%.
... Read the Full Story |
|
Friday's Early Bird Stock Of The Day Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts. | | View Today's Stock Pick |
|
